ArticleJournal of veterinary internal medicine
Effect of the Glucagon-like Peptide-1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus.
Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- iCatCare 2025 consensus guidelines on the diagnosis and management of diabetes mellitus in cats.Journal of feline medicine and surgery · 2025Guideline
- Guidelines for nutritional management of feline diabetes mellitus: a proposed classification system integrating medical considerations.Journal of feline medicine and surgery · 2026Review
- Spectrum of veterinary care in feline diabetes mellitus.Journal of feline medicine and surgery · 2026Review
- Efficacy and Safety of Non-Insulin Antidiabetic Drugs in Cats: A Systematic Review.Animals : an open access journal from MDPI · 2025Review
- Comparative Pharmacological and Pharmaceutical Perspectives on Antidiabetic Therapies in Humans, Dogs, and Cats.Pharmaceutics · 2025Review
- Frequency of diabetic remission, predictors of remission and survival in cats using a low-cost, moderate-intensity, home-monitoring protocol and twice-daily glargine.Journal of feline medicine and surgery · 2024Article
- Feline Comorbidities: Clinical perspective on diabetes mellitus and pancreatitis.Journal of feline medicine and surgery · 2022Review
- Physiological and pharmacological actions of glucagon like peptide-1 (GLP-1) in domestic animals.Veterinary and animal science · 2022Article
- Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2022Article
- Feline comorbidities: Pathophysiology and management of the obese diabetic cat.Journal of feline medicine and surgery · 2021Review
- A genome-wide association study identifies novel candidate genes for susceptibility to diabetes mellitus in non-obese cats.PloS one · 2021Article
- Safety, Tolerability, and Proof-Of-Concept Study of OKV-119, a Novel Exenatide Long-Term Drug Delivery System, in Healthy Cats.Frontiers in veterinary science · 2021Article
- Glycemic variability in newly diagnosed diabetic cats treated with the glucagon-like peptide-1 analogue exenatide extended release.Journal of veterinary internal medicine · 2020Article
- Ultrasonographic assessment of the effect of metoclopramide, erythromycin, and exenatide on solid-phase gastric emptying in healthy cats.Journal of veterinary internal medicine · 2020Article
- Managing feline diabetes: current perspectives.Veterinary medicine (Auckland, N.Z.) · 2018Review
- New Approaches to Feline Diabetes Mellitus: Glucagon-like peptide-1 analogs.Journal of feline medicine and surgery · 2016Review
- Assessment of Exenatide Extended-Release for Maintenance of Diabetic Remission in Cats.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExenatide extended release (ER) is a glucagon-like peptide-1 analogue that increases insulin secretion, inhibits glucagon secretion and induces satiation in humans with type 2 diabetes mellitus. The use of exenatide ER is safe and stimulates insulin secretion in healthy cats.
objectivesThe objective of this study is to assess the safety of exenatide ER and its effect on body weight, remission and metabolic control in newly diagnosed diabetic cats receiving insulin and a low-carbohydrate diet. ANIMALS: Thirty client-owned cats.
methodsProspective placebo-controlled clinical trial. Cats were treated with exenatide ER or 0.9% saline, administered SC, once weekly. Both groups received insulin glargine and a low-carbohydrate diet. Exenatide ER was administered for 16 weeks, or in cats that achieved remission it was given for 4 weeks after discontinuing insulin treatment. Nonparametric tests were used for statistical analysis.
resultsCats in the exenatide ER and placebo groups had transient adverse signs including decreased appetite (60% vs. 20%, respectively, P = .06) and vomiting (53% vs. 40%, respectively, P = .715). Body weight increased significantly in the placebo group (P = .002), but not in cats receiving exenatide ER. Cats on exenatide ER achieved remission or good metabolic control in 40% or 89%, respectively, whereas in control cats percentages were 20% or 58% (P = .427 and P = .178, respectively). CONCLUSION AND CLINICAL IMPORTANCE: Exenatide ER is safe in diabetic cats and does not result in weight gain. Our pilot study suggests that, should there be an additional clinically relevant beneficial effect of exenatide ER in insulin-treated cats on rate of remission and good metabolic control, it would likely approximate 20% and 30%, respectively.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.